Physician profile
Vikram Dayal
NPI 1174515548
$8,234.64
in general payments reported to CMS, 2019-2025
29 companies · $1,279 in 2025
The $1,279 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,132 · 2020: $1,027 · 2021: $1,377 · 2022: $888 · 2023: $549 · 2024: $984 · 2025: $1,279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,290 · Travel and Lodging: $521.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,290.39 |
| Travel and Lodging | $520.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,745.10 | 2019-2024 | Airsupra, Farxiga, Breztri |
| Medtronic, INC. | $1,140.37 | 2024-2025 | Minimed 780g, Mycarelink |
| Abbvie INC. | $1,011.15 | 2021-2025 | Vraylar |
| Glaxosmithkline, LLC. | $611.45 | 2019-2024 | Arexvy |
| Novo Nordisk INC | $590.58 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $557.15 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $522.42 | 2019-2022 | |
| Amgen INC. | $380.63 | 2020-2021 | |
| Abbott Laboratories | $357.20 | 2021-2022 | |
| Lilly USA, LLC | $314.86 | 2019-2023 | Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $236.48 | 2024-2025 | |
| Allergan, INC. | $143.00 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $99.90 | 2021 | |
| Mallinckrodt Enterprises LLC | $83.23 | 2019 | |
| Pfizer INC. | $76.84 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $55.59 | 2025 | The Cologuard Plus Collection Kit |
| Sanofi-Aventis U.S. LLC | $47.84 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $43.38 | 2019-2020 | |
| Genentech USA, INC. | $41.82 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $27.84 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $25.39 | 2019 | |
| Sunovion Pharmaceuticals INC. | $24.70 | 2019 | |
| Mallinckrodt Hospital Products INC. | $18.40 | 2020 | |
| Cranial Technologies, INC | $16.72 | 2020 | |
| Novartis Pharmaceuticals Corporation | $14.31 | 2019 | |
| Phathom Pharmaceuticals, INC. | $13.29 | 2024 | Voquezna |
| Corcept Therapeutics | $12.15 | 2019 | |
| Horizon Therapeutics Plc | $12.03 | 2019 | |
| Shire North American Group INC | $10.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vikram Dayal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.